ArticleBlood2009
The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 185 citations in OpenAlex.
- An ITGA11 expressing subpopulation as predictor for the donor-specific osteogenic capacity of stromal cells.Bone research · 2026Article
- Podocalyxin and ciliary neurotrophic factor receptor are novel components of the surfaceome of chondrogenic cells.Cell communication and signaling : CCS · 2025Article
- Non-Viral Therapy in COVID-19: Where Are We Standing? How Our Experience with COVID May Help Us Develop Cell Therapies for Long COVID Patients.Biomedicines · 2025Review
- Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations.Journal of translational medicine · 2024Review
- Bone marrow stromal cell-derived hepcidin has antimicrobial and immunomodulatory activities.Scientific reports · 2024Article
- CD317Stem cell research & therapy · 2024Article
- Cell surface markers for mesenchymal stem cells related to the skeletal system: A scoping review.Heliyon · 2023Article
- Repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in cynomolgus monkeys by intravenous and subcutaneous injection.Frontiers in cell and developmental biology · 2023Article
- Advances of mesenchymal stem cells and their derived extracellular vesicles as a promising therapy for acute respiratory distress syndrome: from bench to clinic.Frontiers in immunology · 2023Review
- MHC Class I Enables MSCs to Evade NK-Cell-Mediated Cytotoxicity and Exert Immunosuppressive Activity.Stem cells (Dayton, Ohio) · 2022Article
- Intramuscular delivery of neural crest stem cell spheroids enhances neuromuscular regeneration after denervation injury.Stem cell research & therapy · 2022Article
- [Research advances on stem cell therapy for diabetic foot wounds].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Review
- Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy.Frontiers in immunology · 2022Review
- The potential role of integrin alpha 6 in human mesenchymal stem cells.Frontiers in genetics · 2022Article
- Mesenchymal stromal cells for the treatment of ocular autoimmune diseases.Progress in retinal and eye research · 2021Review
- An overview of mesenchymal stem cells and their potential therapeutic benefits in cancer therapy.Oncology letters · 2021Review
- Review
- Identification of Molecules Responsible for Therapeutic Effects of Extracellular Vesicles Produced from iPSC-Derived MSCs on Sjo¨gren's Syndrome.Aging and disease · 2021Article
- Selection of different endothelialization modes and different seed cells for tissue-engineered vascular graft.Bioactive materials · 2021Review
- Cell augmentation strategies for cardiac stem cell therapies.Stem cells translational medicine · 2021Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
We screened for surface proteins expressed only by the early progenitor cells present in low-passage, low-density cultures of the adult stem/progenitor cells from bone marrow referred to as mesenchymal stem cells or multipotent stromal cells (MSCs). Six proteins were identified that were selectively expressed in the early progenitors: podocalyxin-like protein (PODXL), alpha6-integrin (CD49f), alpha4-integrin (CD49d), c-Met, CXCR4, and CX3CR1. All were previously shown to be involved in cell trafficking or tumor progression. Antibodies to CD49f and PODXL, a sialomucin in the CD34 family, were the most robust for FACScan assays. PODXL(hi)/CD49f(hi) MSCs were more clonogenic and differentiated more efficiently than PODXL(lo)/CD49f(lo) cells. Inhibition of expression of PODXL with RNA interference caused aggregation of the cells. Furthermore, PODXL(hi)/CD49f(hi) MSCs were less prone to produce lethal pulmonary emboli, and larger numbers were recovered in heart and kidney after intravenous infusion into mice with myocardial infarcts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.